AGC Pharma Chemicals has announced a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated ecosystem.

This strategic expansion in Barcelona addresses the growing demand for HPAPI driven by advances in oncology and targeted therapies, where highly potent compounds are essential for developing more precise and effective treatments.

With the global HPAPI market valued at USD 25.38 Billion in 2024 and projected to reach USD 47.44 Billion by 2031, growing at a CAGR of 8.13 percent, this state-of-the-art facility backed by a significant investment, is set to redefine API production and set new global standards in pharmaceutical manufacturing excellence.

This strategic enhancement completes AGC Pharma Chemicals’ end-to-end HPAPI capabilities, establishing a comprehensive, fully integrated containment solution that seamlessly connects early-phase development through commercial manufacturing. As a CDMO with HPAPI capabilities from gram to tons, AGC has systematically adapted its entire development and manufacturing chain to OEB5 standards (0.1–1 µg/m³ over an 8-hour shift), from its new R&D facility through laboratory to commercial production, ensuring consistent containment capabilities throughout the entire process.

“Our integrated approach represents AGC’s commitment to supporting the complete HPAPI development journey. By offering an uninterrupted chain of capabilities together, we enable our partners to advance their high-potency compounds from initial grams through commercial tons, all within a single, trusted ecosystem,” states Akihiro Kadokura, CEO at AGC Pharma Chemicals.

This integrated enhancement of AGC’s HPAPI capabilities reinforces its position as a trusted partner in pharmaceutical process development and manufacturing, offering a truly unified solution for advancing high-potency compounds from initial grams through commercial-scale tons.